High Risk of Metabolic Side Effects Among New Paediatric Antipsychotic Users in Sweden—A Register‐Based Study
Pharmacoepidemiology and Drug Safety · 2026
DOI: 10.1002/pds.70482 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2026. Verfasst von Elin Eyfells Kimland und 4 weiteren Autor:innen. Beteiligte Einrichtung: Swedish Medical Products Agency, Uppsala, Sweden. Hauptthemen laut MEDLINE: Antipsychotic Agents, Metabolic Diseases, Obesity. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
This study aims to assess the risk of metabolic side effects among paediatric new users of antipsychotics in Sweden, focusing on differences between substances and sexes.
Methods
Children aged 5–17 years, who were new users of antipsychotics between 2014 and 2021, were identified using Swedish national health registers. Cox' models were fitted for children during first treatment with an antipsychotic, excluding those with eating disorders, yielding hazard ratios (HRs) for metabolic side effects with 95% confidence intervals (CIs).
Results
A total of 5441 children were new users of antipsychotics. Of these, 399 (7.3%; 42% girls) received a new diagnosis or new treatment indicating a metabolic side effect, of which 139 cases during first‐line treatment and without an eating disorder diagnosis. Obesity was the most common metabolic side effect, accounting for 69% of the cases. In girls, significantly increased risks were observed for aripiprazole (HR 3.52, 95% CI 1.58–7.80), olanzapine (HR 6.99, 95% CI 2.34–20.93) and quetiapine (HR 4.87, 95% CI 1.97–12.04), compared with risperidone. Younger girls had higher risks. In boys, a significantly increased risk was found for aripiprazole (HR 2.21, 95% CI 1.37–3.56).
Conclusion
The overall risk of metabolic side effects is considerable, with higher relative risks in girls, especially younger girls. These findings highlight the need for carefully considered treatment and attentive monitoring when initiating antipsychotics in children.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Swedish Medical Products Agency, Uppsala, Sweden.
- Department of Pharmacy, Faculty of Pharmacy, Uppsala University, Uppsala, Sweden.
- Centre for Clinical Research, Region Värmland, Karlstad, Sweden.
- School of Medical Sciences, Örebro University, Örebro, Sweden.
- Unit for Child and Adolescent Psychiatry, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
- Department of Child and Adolescent Psychiatry, Region Halland, Halmstad, Sweden.
ORCID-Profile: Elin Eyfells Kimland, Anders Sundström, Sverre Wikström, Håkan Jarbin, Elin Dahlén
Zitieren
APA
Kimland, E. E., Sundström, A., Wikström, S., Jarbin, H., & Dahlén, E. (2026). High Risk of Metabolic Side Effects Among New Paediatric Antipsychotic Users in Sweden—A Register‐Based Study. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70482
Vancouver
Kimland EE, Sundström A, Wikström S, Jarbin H, Dahlén E. High Risk of Metabolic Side Effects Among New Paediatric Antipsychotic Users in Sweden—A Register‐Based Study. Pharmacoepidemiology and Drug Safety. 2026. doi:10.1002/pds.70482
BibTeX
@article{Kimland2026,
author = {Kimland, Elin Eyfells and Sundström, Anders and Wikström, Sverre and Jarbin, Håkan and Dahlén, Elin},
title = {High Risk of Metabolic Side Effects Among New Paediatric Antipsychotic Users in Sweden—A Register‐Based Study},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2026},
doi = {10.1002/pds.70482}
}
EUVIMED